MapLight Therapeutics Autism Drug Fails Primary Endpoint, Shows Irritability Benefit

Dow Jones

Jun 22

By Adriano Marchese

MapLight Therapeutics said its autism drug failed to meet its primary goal but showed a strong signal in reducing irritability certain adolescents.

The clinical-stage biopharmaceutical said Monday that the mid-stage study of its autism drug ML-004 failed to show an improvement in social communication, the main goal of the trial.

The company noted that an approved pharmacologic therapy for social communication currently doesn't exist.

However, MapLight reported that the therapy showed positive effects on irritability in adolescents with more severe baseline symptoms, a domain with an established regulatory path and limited treatment options.

MapLight said it plans to meet with the Food and Drug Administration to discuss next steps and said it remains well funded ahead of a separate phase 2 readout in schizophrenia expected later in August.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

June 22, 2026 07:59 ET (11:59 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2645162024"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645162024\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645162024?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 19:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645162024","market":"fut","top_or_hot":-1,"title":"MapLight Therapeutics Autism Drug Fails Primary Endpoint, Shows Irritability Benefit","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  MapLight <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said its autism drug failed to meet its primary goal but showed a strong signal in reducing irritability certain adolescents. \n</p>\n<p>\n  The clinical-stage biopharmaceutical said Monday that the mid-stage study of its autism drug ML-004 failed to show an improvement in social communication, the main goal of the trial. \n</p>\n<p>\n  The company noted that an approved pharmacologic therapy for social communication currently doesn't exist. \n</p>\n<p>\n  However, MapLight reported that the therapy showed positive effects on irritability in adolescents with more severe baseline symptoms, a domain with an established regulatory path and limited treatment options. \n</p>\n<p>\n  MapLight said it plans to meet with the Food and Drug Administration to discuss next steps and said it remains well funded ahead of a separate phase 2 readout in schizophrenia expected later in August. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 07:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MapLight Therapeutics Autism Drug Fails Primary Endpoint, Shows Irritability Benefit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMapLight Therapeutics Autism Drug Fails Primary Endpoint, Shows Irritability Benefit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-22 19:59</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  MapLight <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> said its autism drug failed to meet its primary goal but showed a strong signal in reducing irritability certain adolescents. \n</p>\n<p>\n  The clinical-stage biopharmaceutical said Monday that the mid-stage study of its autism drug ML-004 failed to show an improvement in social communication, the main goal of the trial. \n</p>\n<p>\n  The company noted that an approved pharmacologic therapy for social communication currently doesn't exist. \n</p>\n<p>\n  However, MapLight reported that the therapy showed positive effects on irritability in adolescents with more severe baseline symptoms, a domain with an established regulatory path and limited treatment options. \n</p>\n<p>\n  MapLight said it plans to meet with the Food and Drug Administration to discuss next steps and said it remains well funded ahead of a separate phase 2 readout in schizophrenia expected later in August. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 22, 2026 07:59 ET (11:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MPLT","symbol_name":"MapLight Therapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645162024","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645162024","pubTimestamp":1782129540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"MapLight Therapeutics said its autism drug failed to meet its primary goal but showed a strong signal in reducing irritability certain adolescents.The clinical-stage biopharmaceutical said Monday that the mid-stage study of its autism drug ML-004 failed to show an improvement in social communication, the main goal of the trial.The company noted that an approved pharmacologic therapy for social communication currently doesn't exist.However, MapLight reported that the therapy showed positive effects on irritability in adolescents with more severe baseline symptoms, a domain with an established regulatory path and limited treatment options.MapLight said it plans to meet with the Food and Drug Administration to discuss next steps and said it remains well funded ahead of a separate phase 2 readout in schizophrenia expected later in August.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MPLT":"MapLight Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"MapLight Therapeutics自闭症药物未达到主要终点，显示出对易怒的益处","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MPLT":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  MapLight Therapeutics said its autism drug failed to meet its primary goal but showed a strong signal in reducing irritability certain adolescents. \n\n\n  The clinical-stage biopharmaceutical said Monday that the mid-stage study of its autism drug ML-004 failed to show an improvement in social communication, the main goal of the trial. \n\n\n  The company noted that an approved pharmacologic therapy for social communication currently doesn't exist. \n\n\n  However, MapLight reported that the therapy showed positive effects on irritability in adolescents with more severe baseline symptoms, a domain with an established regulatory path and limited treatment options. \n\n\n  MapLight said it plans to meet with the Food and Drug Administration to discuss next steps and said it remains well funded ahead of a separate phase 2 readout in schizophrenia expected later in August. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 07:59 ET (11:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}